Evaluation of drug-drug interaction between Suraxavir Marboxil (GP681) and itraconazole, and assessment of the impact of gene polymorphism
Authors
- Mai Han (ORCID: https://orcid.org/0000-0002-0017-4364)
- Jintong Li (ORCID: https://orcid.org/0009-0002-0844-5496)
- Jiangli Jin (ORCID: https://orcid.org/0000-0002-1704-7732)
- Na Mi (ORCID: https://orcid.org/0000-0003-3090-197X)
- Xin Zhang (ORCID: https://orcid.org/0000-0003-4106-0344)
- Xiaoxue Wang
- Yajuan Li (ORCID: https://orcid.org/0000-0002-5787-0459)
- Yan Zhao (ORCID: https://orcid.org/0000-0002-7760-916X)
- Gang Cui (ORCID: https://orcid.org/0000-0003-3744-5209)
- Xianbo Zuo (ORCID: https://orcid.org/0000-0002-0212-2664)
- Chunyan Xiao (ORCID: https://orcid.org/0009-0001-1999-8961)
- Wei Wu (ORCID: https://orcid.org/0000-0003-4228-2416)
- Jing Wang (ORCID: https://orcid.org/0009-0005-4564-6010)
Institutions
- China-Japan Friendship Hospital (CN)
- Buchang Pharma (China) (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-04-11
- DOI
- https://doi.org/10.3389/fphar.2024.1505557
- Citations
- 3
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 4.06